background image

Paid Clinical Trials Des Moines

Discover 237 paid clinical trials in Des Moines, Iowa. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

for
Ovarian Cancer
Location: Des Moines IA, Oklahoma City OK, Austin TX, Houston TX,
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 50 - 70+

Code: NCT00539162

Recruiting
Active & Responsive

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

for
Relapsed or Refractory Multiple Myeloma
Location: Waukee IA, Fort Sam Houston TX, Silver Spring MD,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT05572515

Phase3, Recruiting

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.

for
Chronic Lymphocytic Leukemia
Location: Des Moines IA, Omaha NE, Grand Island NE, Milwaukee WI,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT06524375

Phase2, Recruiting

Remote Ischemic Conditioning Using the autoRIC

for
Ischemia-Reperfusion Injury
Location: Des Moines IA, Kansas City MO, West Bloomfield MI,
Sponsor: CellAegis US, Inc.

Sex: All

Age: 18+

Code: NCT03318575

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

for
Locally Advanced Head and Neck Squamous Cell Carcinoma
Location: Des Moines IA, Kansas City KS, Columbia MO, Sioux Falls SD,
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT06129864

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

By submitting, you consent to the use of your personal details, including contact information and location, to respond to your request for information related to clinical trials, as outlined in the Privacy Policy. If at any time you want to discontinue receiving alerts, please click the Unsubscribe link in the email received.

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for
Breast Cancer
Location: Des Moines IA, Omaha NE, Albert Lea MN, Lincoln NE,
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

for
Chronic Lymphocytic Leukemia
Location: Des Moines IA, Kansas City MO, Springfield IL, Dyer IN,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06428019

Phase3, Recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

for
Diffuse Large B-Cell Lymphoma
Location: Des Moines IA, Lubbock TX, Beltsville MD, Towson MD, Orange CA,
Sponsor: AstraZeneca

Sex: All

Age: 65 - 70+

Code: NCT05952024

Phase2, Recruiting

Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis,
Location: Des Moines IA, Lincoln NE, Louisville KY, Nashville TN,
Sponsor: Kartos Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06479135

Phase3, Recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

for
AL Amyloidosis
Location: Des Moines IA, Ankeny IA, Bellevue NE, Omaha NE,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06022939

Phase3, Recruiting